Comments
Loading...
Y-mAbs Therapeutics Stock Guidance | NASDAQ:YMAB | Benzinga
Y-mAbs Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/04/2025 | YMAB | Y-mAbs Therapeutics | Q1 | 2025 | — | — | — | $18.00M | $21.00M | $24.37M | Get Alert |
| 03/04/2025 | YMAB | Y-mAbs Therapeutics | FY | 2025 | — | — | — | $75.00M | $90.00M | $105.76M | Get Alert |
| 01/10/2025 | YMAB | Y-mAbs Therapeutics | FY | 2024 | — | — | — | $88.00M | $88.00M | $88.53M | Get Alert |
| 11/08/2024 | YMAB | Y-mAbs Therapeutics | FY | 2024 | — | — | — | $87.00M | $95.00M | $91.67M | Get Alert |
| 08/12/2024 | YMAB | Y-mAbs Therapeutics | FY | 2024 | — | — | — | $87.00M | $95.00M | $95.18M | Get Alert |
| 05/07/2024 | YMAB | Y-mAbs Therapeutics | FY | 2024 | — | — | — | $95.00M | $100.00M | $97.16M | Get Alert |
| 02/29/2024 | YMAB | Y-mAbs Therapeutics | FY | 2024 | — | — | — | $95.00M | $100.00M | $96.27M | Get Alert |
| 01/09/2024 | YMAB | Y-mAbs Therapeutics | FY | 2023 | — | — | — | $80.00M | $85.00M | $82.39M | Get Alert |
| 11/13/2023 | YMAB | Y-mAbs Therapeutics | FY | 2023 | — | — | — | $80.00M | $85.00M | $83.76M | Get Alert |
| 08/10/2023 | YMAB | Y-mAbs Therapeutics | FY | 2023 | — | — | — | $80.00M | $85.00M | $82.79M | Get Alert |
| 11/07/2022 | YMAB | Y-mAbs Therapeutics | FY | 2022 | — | — | — | $45.00M | $50.00M | $51.75M | Get Alert |
| 08/08/2022 | YMAB | Y-mAbs Therapeutics | FY | 2022 | — | — | — | $45.00M | $50.00M | $60.18M | Get Alert |
| 04/27/2022 | YMAB | Y-mAbs Therapeutics | Q1 | 2022 | — | — | — | $10.50M | $10.50M | $10.99M | Get Alert |
| 04/27/2022 | YMAB | Y-mAbs Therapeutics | FY | 2022 | — | — | — | $45.00M | $50.00M | $67.81M | Get Alert |
FAQ
What is the most recent guidance for Y-mAbs Therapeutics (YMAB)?
There have been no specific sales or earnings guidance reported for Y-mAbs Therapeutics in recent months.
Browse guidance and forecast on all stocks.